ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

COYA vs RTSN // ALTMAN Z-SCORE & DEBT/EQUITY

Coya Therapeutics Inc. (NASDAQ) VS. Retension Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: COYA 1 — RTSN 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COYA VS. RTSN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC COYA RTSN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% — — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -11.50% — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 123.60% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE 6.08 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 — — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 27.5 54.8 -27.30 RTSN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $93.4M $93.2M $122.9K COYA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR COYA REV RTSN REV COYA GROSS % RTSN GROSS % COYA FCF RTSN FCF
FY 2025 $7.9M — — — -$10.7M —
FY 2024 $3.6M — — — -$10.3M —
FY 2023 $6.0M — — — -$11.2M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COYA // BETA —
RTSN // BETA —